1-8 of 8
Julia Piasecki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R. Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur S. Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G. Berdeja, Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-McKiver, Sergio A. Giralt
Journal: Blood
Blood (2023) 142 (Supplement 1): 1028.
https://doi.org/10.1182/blood-2023-178933
Published: 2023
Journal Articles

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3

Rachid Baz, Paula Rodriguez Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Ajay K. Nooka, Luciano Costa, Noopur S. Raje, Ingerid Weum Abrahamsen, Michel Delforge, Usama Gergis, Douglas W. Sborov, Sergio A. Giralt, Marc S. Raab, Tadao Ishida, Asya Varshavsky-Yanovsky, Taewoong Choi, Larry D. Anderson, Jr., Anna Truppel-Hartmann, Rashmi Bhatnagar, Fan Wu, Julia Piasecki, Jasper Felten, Andrea Caia, Mark Cook, Yi Lin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4879.
https://doi.org/10.1182/blood-2023-174477
Published: 2023
Journal Articles

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA, Todd Devries, PhD, Aditya Radhakrishnan, PhD, Yan Li, PhD, Mark Heipel, BS, Brian A. Fox, PhD, Valeria Beckett, MS, Mariana Cota Stirner, MD PhD, Kristin Conte, MPH, Thomas Doerr, MSc, Sham Mailankody, MBBS, Sandy W. Wong, MD, Philip L. McCarthy, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-137786
Published: 2020
Journal Articles

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Lucrezia Colonna, PhD, Garnet Navarro, BS, Todd Devries, PhD, Valeria Beckett, MS, Anthony Amsberry, BS, Aditya Radhakrishnan, PhD, Julia Piasecki, BA, Mark Heipel, BS, Yan Li, PhD, Uma Kavita, PhD, Melissa G Works, PhD, Mirna Mujacic, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136748
Published: 2020
Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 957.
https://doi.org/10.1182/blood-2018-99-113548
Published: 2018
Journal Articles

In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.

Jiangchun Xu, MD, PhD, Evy D. Leenheer, Ph.D., Julia Piasecki, MS, Anne-Renee V. De Vries, Ph.D., Karin Vanderkerken, Ph.D., Peter Croucher, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 1518.
https://doi.org/10.1182/blood.V110.11.1518.1518
Published: 2007
Journal Articles

MGMT (P140K) Allows for Efficient and Sustained In Vivo Selection in Non-Human Primates.

Brian C. Beard, PhD, Kate Beebe, BS, Julia Piasecki, BS, Christina Gooch, BS, David Dickerson, BS, Hans-Peter Kiem, MD
Journal: Blood
Blood (2006) 108 (11): 3270.
https://doi.org/10.1182/blood.V108.11.3270.3270
Published: 2006